Oncology & radiation denials: appealing drug-compendia and technique denials

Oncology denials usually involve a drug the plan considers off-label or off-compendium, or a radiation technique (such as IMRT or proton therapy) the plan wants downgraded to a less intensive modality. The strongest appeals tie the regimen to recognized compendia and guidelines and document why the specific technique is medically necessary. Appeals that are actually filed in radiation oncology are overturned at a high rate, which makes filing the high-value default.

Why these denials happen

Cancer-drug denials turn on compendium and guideline support for the indication and line of therapy; recognized compendia and NCCN guidance are the reference points payers and Medicare use. Radiation denials turn on technique medical necessity — whether IMRT, SBRT, or proton therapy is justified over a less intensive modality for the specific anatomy and goals. The denial is usually about documentation of the indication or the technique rationale, not the legitimacy of treating the cancer.

The common denials

• Drug deemed off-label or off-compendium for the indication or line of therapy.
• Radiation technique (IMRT, SBRT, proton) denied in favor of a less intensive modality.
• Prior authorization criteria for the regimen or modality not documented.
• Site-of-care steering away from a hospital outpatient department.
• Genomic test or companion diagnostic not established as medically necessary.

Is it worth appealing?

How to appeal

1. 1

   Cite the compendia for the regimen

   Tie the drug, indication, and line of therapy to recognized compendia and NCCN guidance — the references payers and Medicare use to judge off-label use.

2. 2

   Justify the radiation technique

   Document why IMRT, SBRT, or proton therapy is medically necessary for the specific anatomy, dose constraints, and goals over the plan's preferred modality.

3. 3

   Move quickly and escalate

   Oncology is time-sensitive — use expedited review where delay risks harm, and escalate to external review, where filed oncology appeals do well.

Frequently asked

Clinical-coverage patterns and guideline references are summarized for plain-language reference and vary by plan and payer policy. This is general information for clinicians and billing staff, not medical, legal, or coding advice — confirm against the governing coverage policy and the current guideline for each claim.